The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months
2006

The Magpie Trial: Effects of Magnesium Sulphate on Children at 18 Months

Sample size: 4483 publication Evidence: moderate

Author Information

Author(s): Magpie Trial Follow-Up Study Collaborative Group

Hypothesis

Does in utero exposure to magnesium sulphate for pre-eclampsia affect the child's chance of surviving without major neurosensory disability?

Conclusion

Magnesium sulphate for pre-eclampsia was not associated with a clear difference in the risk of death or disability for children at 18 months.

Supporting Evidence

  • Of those allocated magnesium sulphate, 15.0% had death or neurosensory disability at 18 months.
  • Children exposed to magnesium sulphate did not show a significant difference in risk of neurosensory disability compared to placebo.
  • 73% of children included in follow-up were contacted.

Takeaway

This study looked at children whose mothers took magnesium sulphate during pregnancy. It found that it didn't really change the chances of the children being healthy or having problems at 18 months old.

Methodology

Children were assessed at 18 months using questionnaires, interviews, and neurodevelopmental testing.

Potential Biases

There was a risk of bias in follow-up due to difficulties in contacting families, especially in high PNM countries.

Limitations

Some children could not be followed up, and the study had less power than the original trial due to not including all children randomised.

Participant Demographics

Children were born to women with pre-eclampsia from 125 centres in 19 countries.

Statistical Information

Confidence Interval

95% CI 0.90–1.25

Digital Object Identifier (DOI)

10.1111/j.1471-0528.2006.01165.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication